MedTrace Logo

Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF)

NCT02389933 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2021-02-15

No results posted yet for this study

Summary

Novartis has set up this global Multiple Patient Program (MPP) treatment plan to provide access to life-saving treatment with LCZ696 for patients that were not previously exposed to LCZ696 but have no other option to receive LCZ696 in their country prior to market authorization OR commercial availability, based on local regulatory and legal requirements.

Conditions

  • Heart Failure With Reduced Ejection Fraction (HF-rEF)

Interventions

DRUG

LCZ696

immediate release film coated tablet in 50 mg, 100 mg, 200 mg, and 400 mg strengths for oral administration.

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States
  • Australia
  • Austria
  • Brazil
  • Croatia
  • Cyprus
  • France
  • Germany
  • Greece
  • Ireland
  • Lebanon
  • Malta
  • Panama
  • Philippines
  • Slovenia
  • Spain
  • Switzerland
  • United Arab Emirates

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02389933 on ClinicalTrials.gov